Abstract
Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype. Prognostic correlates of cytopenic phenotype were explored in 886 ruxolitinib-treated patients with primary/secondary MF (PMF/SMF) included in the RUX-MF retrospective study. Cytopenia was defined as: leukocyte count <4×109 /L and/or hemoglobin <11/<10g/dL (males/females) and/or platelets <100×109 /L. Overall, 407 (45.9%) patients had a cytopenic MF, including 249 (52.4%) with PMF. In multivariable analysis, high molecular risk mutations (p=.04), intermediate 2/high Dynamic International Prognostic Score System (p<.001) and intermediate 2/high Myelofibrosis Secondary to Polycythemia Vera and Essential Thrombocythemia Prognostic Model (p<.001) remained associated with cytopenic MF in the overall cohort, PMF, and SMF, respectively. Patients with cytopenia received lower average ruxolitinib at the starting (25.2mg/day vs. 30.2mg/day, p<.001) and overall doses (23.6mg/day vs. 26.8mg/day, p<.001) and achieved lower rates of spleen (26.5% vs. 34.1%, p=.04) and symptom (59.8% vs. 68.8%, p=.008) responses at 6months compared with patients with the proliferative phenotype. Patients with cytopenia also had higher rates of thrombocytopenia at 3months (31.1% vs. 18.8%, p<.001) but lower rates of anemia (65.6% vs. 57.7%, p=.02 at 3months and 56.6% vs. 23.9% at 6months, p<.001). After competing risk analysis, the cumulative incidence of ruxolitinib discontinuation at 5years was 57% and 38% in patients with cytopenia and the proliferative phenotype (p<.001), whereas cumulative incidence of leukemic transformation was similar (p=.06). In Cox regression analysis adjusted for Dynamic International Prognostic Score System score, survival was significantly shorter in patients with cytopenia (p<.001). Cytopenic MF has a lower probability of therapeutic success with ruxolitinib as monotherapy and worse outcome. These patients should be considered for alternative therapeutic strategies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
